Browsing: GLP-1 Receptor Agonists

A 2-year pragmatic open-label trial finds once-weekly semaglutide modestly outperforms physician-chosen alternatives on HbA1c targets, with a year-1 weight advantage that fades by year 2. PICO summary and commentary.

A small mechanistic trial in youth-onset type 2 diabetes finds metformin and liraglutide shift gut bacteria and bile acids; bile-acid metabolites, not microbiota shifts, track with glucose. PICO summary and commentary.

A clamp study finds tirzepatide preserves the glucagon defence against hypoglycaemia but delays cortisol/noradrenaline and lowers symptom scores, while awareness is unchanged. PICO summary and commentary.

Summary: In adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes…

A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.

📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context GLP-1 receptor…

A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.

A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.

A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.

A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.